|
| Exchange Disseminated Time | Venus Remedies Ltd has informed BSE regarding "Venus Remedies to expand innovations basket with Sulbactomax Patent from Russia & Ukraine"
Press Release:
"We are pleased to inform you that the Company has received patent grants for SULBACTOMAX, one of the key research products of company, from Federal service on Intellectual Property, Patents and Trademarks (ROSPATENT), Russia and state Enterprise Ukrainian Institute of Industrial Property Ukraine. With grant of these patents Venus has SULBACTOMAX patent granted in a total of 41 countries all around the globe.
Sulbactomax, an existing 2 million USD product in Ukraine, with the grant of this patent will further strengthen its existence in Ukraine Pharmaceutical market which is growing at the rate of 20.9 percent CAGR through to 2014. The Russian patent has opened doors for Venus to enter the Russian Cephalosporin Market of $780m which is the world's 11th largest pharmaceutical market.
Sulbactomax is a novel antibiotic combination of Beta-lactam ceftiaxone & Beta-lactamase inhibitor. A multi-centric phase III clinical trial on 594 patients has been just completed on sulbactomax on additional indications like Skin and skin structure infections, Otitis media, Surgical infections, Bone and joint infections and Septicemia. Sulbactomax along with a chemical vector as third ingredient indicated for the treatment of infections of Respirator Tract complicated and uncomplicated urinary tract infections and other serious infections caused by beta-lactamse producing celtriaxone resistant bacterial strains." (For more details kindly refer Corporate Announcements on www.bseindia.com). |
|
|